NCT00387413 - A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Hyperalgesia

Interventions

DRUG

Duloxetine

Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.

DRUG

GSK189254

Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.

DRUG

GSK189254 Placebo

Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.

DRUG

Duloxetine Placebo

Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.

Trial Locations (1)

CB2 0QQ

GSK Investigational Site, Cambridge